Articles on analgesics from NPS RADARArticles on analgesics from NPS RADAR

Title Content Type Date Description
Oxycodone-with-naloxone controlled-release tablets (Targin) for chronic severe pain Professional publication - NPS RADAR - Review 2011-12-01 00:00:00 The tablets provide equivalent analgesia to that of oxycodone controlled release tablets. The addition of naloxone reduces, but does not eliminate, opioid-induced constipation.
Paracetamol with caffeine (Panadol Extra) available over the counter from pharmacies Professional publication - NPS RADAR - Brief item 2010-08-01 00:00:00 Paracetamol with caffeine (Panadol Extra) available over the counter from pharmacies
Hydromorphone prolonged-release tablets (Jurnista) for chronic severe disabling pain Professional publication - NPS RADAR - Brief item 2009-05-01 00:00:00 Hydromorphone prolonged-release (Jurnista), a once-daily long-acting opioid, was listed on the Pharmaceutical Benefits Scheme on 1 May 2009. It is available as a restricted benefit for chronic severe disabling cancer or non-cancer pain not responding to non-opioid analgesics.
Once-daily tramadol extended-release (Durotram XR) for pain Professional publication - NPS RADAR - Review 2008-12-01 00:00:00 Three different formulations of tramadol are now available in Australia: immediate-release, taken every 4–8 hours; sustained-release, taken twice daily; and extended-release, taken once daily. Tramadol extended-release (Durotram XR) is a biphasic formulation of tramadol: 25% of the dose is released within 2 hours, while the remaining 75% is gradually released over 24 hours. Tramadol extended-release taken once daily has similar efficacy to that of twice-daily tramadol.
Fentanyl lozenges (Actiq) for breakthrough cancer pain Professional publication - NPS RADAR - Review 2008-04-01 00:00:00 Information on use of fentanyl lozenges (Actiq) for breakthrough cancer pain, including safety concerns and dosing issues.
Erratum: Fentanyl patches (Durogesic) for chronic pain Professional publication - NPS RADAR - Brief item 2006-12-01 00:00:00 Information about equi-analgesic doses of methadone have been removed from 'Table 1: Equipotency of opioid analgesics to oral morphine 30 mg', in the Dosing Issues section of this NPS RADAR review published in the August 2006 issue.
Fentanyl patches (Durogesic) for chronic pain Professional publication - NPS RADAR - Review 2006-10-01 00:00:00 Reviews use of fentanyl patches for chronic pain, including patient selection and education, safety profile, and general analgesia guidelines.
Lumiracoxib (Prexige) for osteoarthritis Professional publication - NPS RADAR - Review 2006-08-01 00:00:00 Reports urgent withdrawal of lumiracoxib by TGA because of serious liver adverse effects and includes review of lumiracoxib use for osteoarthritis.
Buprenorphine transdermal patches (Norspan) for chronic severe pain Professional publication - NPS RADAR - Review 2005-12-01 00:00:00 Reviews use of buprenorphine skin patches for chronic severe non-cancer pain, including adverse effects, contraindications, and treatment of overdose.
Elevated cardiovascular risk with NSAIDs? Professional publication - NPS RADAR - Review 2005-08-01 00:00:00 Reviews evidence of elevated cardiovascular risk associated with COX-2 selective NSAIDs and provides guidelines for NSAID use and risk assessment.
Triptans for migraine Professional publication - NPS RADAR - Review 2004-02-01 00:00:00 PBAC has increased maximum quantity of naratriptan, sumatriptan, and zolmitriptan to 4 tablets with 5 repeats for patients with more than one migraine each month.

NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.

RSS FeedRSS feed

Date published: 2009-10-28 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.